Status:
COMPLETED
Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
Lead Sponsor:
Meda Pharmaceuticals
Collaborating Sponsors:
Novella Clinical
Conditions:
Allergic Rhinitis
Eligibility:
All Genders
6-5 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an...
Detailed Description
Approximately 200 subjects, between the ages of ≥ 6 months to \< 6 years of age who have a history of AR will participate in this study. The study will be conducted at about 20 research centers in th...
Eligibility Criteria
Inclusion
- Male and female subjects \>6 months to \<6 years, inclusive at the screening visit
- A history of AR
- The parent must provide written informed consent and the child must provide assent, if possible
- Willing and able to comply with the study requirements
- May benefit from treatment with Astepro Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subject's clinical condition, at both the Screening and Randomization Visits
- General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
- Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)
Exclusion
- On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation
- Other nasal disease(s) likely to affect deposition of intranasal medication, such as acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities
- Nasal surgery or sinus surgery within the previous year
- Chronic sinusitis
- The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study
- Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
- Respiratory tract infections within two weeks prior to Visit 1.
- Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators are eligible for enrollment. Asthma (with the exception of intermittent asthma). Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment
- Chronic obstructive sleep apnea syndrome (clinical diagnosis)
- Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial
- Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives -- Family members of research center or private practice personnel who are directly involved in this study are excluded
- Members of the same family cannot enroll in the study at the same time.
- Subjects who have used medications or therapies that could interfere with safety evaluations (see Section 4.0)
- Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
191 Patients enrolled
Trial Details
Trial ID
NCT01880840
Start Date
June 1 2013
End Date
August 1 2014
Last Update
June 29 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Center of Alabama,LLC
Birmingham, Alabama, United States, 35209
2
Little Rock Allergy and Asthma Clinical research Center
Little Rock, Alaska, United States, 72205
3
West Coast Clinical Trials
Costa Mesa, California, United States, 92626
4
Southern California Research
Mission Viejo, California, United States, 92691